Meticil (ANTIBACTERIALS)

Quick links to important sections

Meticil (ANTIBACTERIALS)

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meticil (ANTIBACTERIALS)

Property Description
Active Ingredients Ampicillin, Diclofenac
Form Combination capsule/tablet or injection solution
Pharmacological Class Aminopenicillin Antibiotic & Nonsteroidal Anti-Inflammatory Drug (NSAID)
Origin Semisynthetic beta-lactam (Ampicillin) & Synthetic Organic Compound (Diclofenac)

Meticil is a fixed-dose combination product containing the antibiotic Ampicillin and the Nonsteroidal Anti-Inflammatory Drug (NSAID) Diclofenac. This synthetic drug is classified as a dual-action medicine, designed to address both the underlying cause of a bacterial infection and its accompanying inflammatory symptoms simultaneously.


What Type of Medicine is Meticil? (Definition and Classification)

Meticil is a distinct combination medicine consisting of an aminopenicillin antibiotic and an NSAID. The Ampicillin component is a semisynthetic beta-lactam with broad-spectrum activity that works by killing susceptible bacteria. Diclofenac, a phenylacetic acid derivative, is included to manage inflammation, pain, and fever.

This pairing represents a streamlined therapeutic approach, combining an antimicrobial agent with an anti-inflammatory agent. The product is typically available as a combination capsule or tablet for oral use, or as a sterile injection solution for parenteral administration, depending on the specific product formulation.


Composition and General Purpose of the Combination (Composition and Benefit)

The rationale behind Meticil's composition is to deliver a coordinated defense. The Ampicillin component provides the curative action by disrupting the bacterial cell wall, while the Diclofenac provides symptomatic relief. The inclusion of the anti-inflammatory component is intended to help reduce inflammation and pain often associated with acute infections.

The general purpose of this medicine is therefore to facilitate the clearance of the bacterial infection while mitigating the painful, inflammatory symptoms often experienced during the acute phase of illness, representing a targeted approach for complex conditions.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

What side effects are possible with Meticil (ANTIBACTERIALS)?

Possible Side Effects and Safety Information

The safety profile of Meticil (metronidazole) is defined by common gastrointestinal disturbances and potential for serious adverse reactions, primarily affecting the nervous system and skin.

Common Adverse Reactions

The most commonly reported side effects typically involve the gastrointestinal system and head, categorized as common in regulatory reports. These may include:

  • Nausea and vomiting
  • Diarrhea or constipation
  • Abdominal cramping or epigastric distress
  • Headache and anorexia (loss of appetite)

Serious and Clinically Significant Risks

Serious adverse reactions, though less frequent, have been documented and warrant immediate medical evaluation if they occur:

  • Central and Peripheral Nervous System Effects: These can include encephalopathy (brain disease), convulsive seizures, aseptic meningitis, and peripheral neuropathy (tingling or numbness in extremities). The appearance of any abnormal neurological signs requires prompt risk re-evaluation.
  • Severe Cutaneous Adverse Reactions (SCARs): Life-threatening skin reactions such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported.
  • Blood Dyscrasias: Meticil is associated with mild, transient leukopenia (low white blood cell count) and should be used with caution in patients with a history of blood dyscrasias.

Safety Restrictions and Monitoring

Official safety documents define specific restrictions and requirements for monitoring:

  • Drug-Alcohol Interaction: Meticil must not be used concurrently with alcohol or propylene glycol-containing products during therapy and for at least three days afterward, due to the risk of a severe disulfiram-like reaction (flushing, vomiting, abdominal cramps).
  • Drug-Drug Contraindication: Co-administration with Disulfiram is contraindicated due to the potential for psychotic reactions.
  • Anticoagulants: If used with Warfarin or other oral anticoagulants, prothrombin time and International Normalized Ratio (INR) must be carefully monitored, as Meticil may potentiate the anticoagulant effect.
  • Carcinogenicity: The drug has shown carcinogenic activity in chronic animal studies, and unnecessary use should be avoided.
  • Special Populations: Caution is advised in patients with severe hepatic or end-stage renal impairment due to potential accumulation of the drug or its metabolites. Use is contraindicated in patients with Cockayne Syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the overdose profile for Meticil by the recognized severe effects of its active components, Ampicillin and Diclofenac. Immediate medical attention must be sought for any suspected overdose.

Documented Overdose Presentations

System Manifestations (as documented in regulatory sources)
Gastrointestinal Nausea, Vomiting (potentially with blood), Severe Abdominal Pain, or signs of Internal Bleeding.
Neurological Drowsiness, Confusion, Agitation, Seizures, or Coma (in severe cases).
Renal Symptoms of acute kidney damage, such as little or no urine output.

Emergency Actions Required

Contact emergency services immediately if the individual exhibits severe signs, including collapse, a seizure, trouble breathing, or inability to be awakened. These are life-threatening outcomes documented in the regulatory profile. The management is limited to symptomatic and supportive treatment, as no specific antidote is known for this combination.

Severe Outcome Risk Population-Specific Note
Fatal Gastrointestinal Bleeding is a serious outcome documented for the NSAID component. Elderly patients are at greater risk for serious gastrointestinal events.
Hospital monitoring, including ECG and blood/urine tests, is required. Patients with renal impairment are at increased risk for CNS effects, such as seizures.

Therapeutic Uses of Meticil (ANTIBACTERIALS)

What Meticil Treats: Main Uses and Benefits

The primary role of Meticil (Ampicillin/Diclofenac) is to provide dual-action therapeutic support for illnesses generally characterized by both a susceptible bacterial infection and a significant inflammatory response. The NSAID component is intended for use to help with pain, tenderness, swelling, and stiffness associated with inflammatory states.

Treatment Context and Benefit

This medication is commonly used to support the process of addressing the bacterial presence across conditions presenting with acute episodes caused by Ampicillin-susceptible bacteria. These are relevant in contexts such as certain respiratory tract infections, specific urinary tract infections (UTIs), and susceptible gastrointestinal infections.

This dual approach is applied in clinical settings where both the eradication of the pathogen and the appropriate management of distressing symptoms are relevant.

The combination is relevant in contexts where the infection causes pronounced systemic discomfort, particularly acute fever and moderate to severe pain. This provides symptomatic relief that generally contributes to improved day-to-day comfort and assists with maintaining functional stability during symptomatic periods. The supportive relief helps ease the overall burden of symptoms during the recovery phase.


Quick Fact: Symptomatic Relief

Meticil is applied across domains where additional symptomatic support is relevant, helping to manage symptoms that interfere with daily comfort and conditions characterized by periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for Meticil, a fixed-dose combination containing Ampicillin and Diclofenac, is determined by the most restrictive regulatory rules of both components. Absolute contraindications exclude several groups.

Who Must Not Use Meticil

  • Individuals with a history of hypersensitivity to any penicillin, beta-lactam drug, Diclofenac, or any NSAID.
  • Patients with aspirin-sensitive asthma or a history of allergic-type reactions after taking aspirin or other NSAIDs.
  • Patients with concomitant Infectious Mononucleosis.
  • Women at 30 weeks gestation and later in pregnancy, or those undergoing Coronary Artery Bypass Graft (CABG) surgery.
  • Patients with established Ischaemic Heart Disease, Cerebrovascular Disease, or severe Congestive Heart Failure (NYHA Class II–IV).
  • Those with active gastrointestinal ulceration, bleeding, or perforation, or severe hepatic or severe renal impairment.

Conditional and Restricted Use

Use is generally established for adults and adolescents aged 12 years and older. Safety and effectiveness are not established for children younger than 12 years. Elderly patients require careful consideration due to increased risk of cardiovascular and gastrointestinal events. Use must be avoided in patients with a recent Myocardial Infarction (MI) or advanced renal disease unless the benefits outweigh the risks. Use during lactation is not generally recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Meticil, a fixed-dose combination of Ampicillin and Diclofenac, carries the interaction profiles of both components, as documented by regulatory agencies.


Diclofenac (NSAID) Interactions

The Diclofenac component is formally contraindicated in patients who have a history of asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs, and in the setting of coronary artery bypass graft (CABG) surgery.

Co-administration with anticoagulants (e.g., Warfarin) and antiplatelet agents increases the documented risk of bleeding due to a pharmacodynamic interaction. Diclofenac may also increase the plasma concentrations of co-administered drugs like Digoxin and Lithium by reducing their clearance. Furthermore, Diclofenac can diminish the antihypertensive effect of ACE Inhibitors and ARBs. Regulatory documents note that the severity of renal function deterioration risk is heightened in elderly or renally impaired patients when combining Diclofenac with ACE inhibitors/ARBs.


Ampicillin (Antibiotic) Interactions

Probenecid is documented to decrease the renal tubular secretion of Ampicillin, resulting in an increased and prolonged plasma concentration of the antibiotic component. The risk of developing a skin rash is substantially increased when co-administered with Allopurinol. The Ampicillin component may also reduce the effectiveness of oral contraceptives. Because food may reduce Ampicillin absorption, oral formulations are advised to be administered one hour before or two hours after meals.

Mechanism of Action

How Meticil (ANTIBACTERIALS) Works

Meticil, a beta-lactam antibacterial, exerts its action by targeting critical enzymes involved in the synthesis of the bacterial cell wall, resulting in impaired structural integrity. This mechanism is selective as the target structures are unique to prokaryotic cells.


Inhibition of Peptidoglycan Cross-Linking

This mechanistic domain involves Meticil's molecular mimicry of the D-Ala-D-Ala structure, allowing it to act within domains involving enzyme-mediated signaling. The compound covalently and irreversibly binds to Penicillin-Binding Proteins (PBPs), which are transpeptidase enzymes essential for cross-linking peptidoglycan polymers. This modification of early molecular steps prevents the final structural assembly, which alters the cell wall's rigidity.


Loss of Structural Integrity and Osmotic Lysis

By inhibiting PBP activity, Meticil initiates a cascade that modifies the final assembly of the cell wall structure. This engagement with mechanisms that regulate bacterial structural integrity leads to a destabilization of the cell membrane due to the continuous activity of autolytic enzymes and the high internal osmotic pressure of the bacterial cell. The osmotic pressure acting against the altered cell structure causes subsequent osmotic lysis.

Dosage and Administration Information

Meticil is a fixed-dose combination product whose use is based on the administration guidelines for its two components, Ampicillin and Diclofenac. The medication is delivered either through the oral route as a capsule or tablet, or through the parenteral route via intramuscular (IM) injection or slow intravenous (IV) injection/infusion.

The standard adult dosing for the Ampicillin component typically requires a regimen of 250 mg to 500 mg per dose, taken in four equally divided doses daily to maintain consistent systemic levels. For the oral form, administration must occur at the start of a meal to enhance gastrointestinal tolerance. In cases of severe systemic infection, the parenteral dose of the antibiotic component may be increased up to 2 grams per administration.

The course duration for the antibiotic must extend a minimum of 48 to 72 hours after symptoms have fully resolved, or a required 10 days for specific streptococcal infections. In contrast, the symptomatic component, Diclofenac, has a restriction on its parenteral use, which should not exceed 150 mg daily and is generally limited to a maximum of two days before switching to an oral form.

A dose reduction or interval extension is specified for the Ampicillin component in patients with severe renal impairment (creatinine clearance below 10 ml/min). Furthermore, parenteral solutions must be freshly prepared and administered immediately, with IV injection occurring slowly over three to four minutes.

Recent Clinical Evidence

Research evidence / Overview of Studies for Meticil (ANTIBACTERIALS)

The research foundation for Meticil, a fixed-dose combination of the antibiotic Ampicillin and the nonsteroidal anti-inflammatory drug (NSAID) Diclofenac, is primarily derived from studies evaluating the actions of its two components. The research base explores its use in settings related to microbiological clearance and the management of acute inflammatory symptoms often observed during an infection.


Research Evidence for the Antibacterial Component (Ampicillin)

The research base for the Ampicillin component focuses on its activity against bacteria. This component was studied in research contexts involving microbiological clearance across susceptible bacterial conditions, such as those observed in the urinary, respiratory, and gastrointestinal tracts. The core research base consists of Randomized Controlled Trials (RCTs) and systematic reviews that monitored the antibiotic component and its relationship to microbiological clearance. Findings described patterns observed in the studies where research monitored how the target bacteria evolved in the observed populations.

Studies on Symptom Management and Dual-Action Use (Diclofenac)

Studies monitored the use of the Diclofenac component, which is an NSAID, in conditions associated with acute or disruptive episodes, such as those involving fever and pain. Research highlights changes measured during the study period for outcomes related to physical discomfort, specifically patient-reported pain scores and temperature measurements in participants receiving the anti-inflammatory drug. The fixed-dose combination product was observed in some limited studies exploring short-term symptom changes. These limited studies examined the product’s use in contexts involving acute symptoms, with findings describing how symptoms evolved in the observed populations.


What is Still Uncertain About the Research Base

The evidence concerning the specific fixed-dose combination versus the antibiotic component alone remains limited and heterogeneous. The research base has several documented limitations. Comparative evidence is lacking for the fixed-dose combination against the antibiotic administered alone. Furthermore, studies on the combination had sample sizes that were modest in some instances, and follow-up durations were limited. Some in vitro research has explored the interaction of NSAIDs and antibiotics, with findings suggesting patterns that may alter the activity of antimicrobial drugs, indicating an area that research is ongoing to explore clinically.

Key Studies & References

  1. Diclofenac Drug Information (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Meticil (ANTIBACTERIALS) (FAQ)

Q: Does Meticil cause stomach upset or diarrhea often?

A: According to official product information, gastrointestinal reactions, including diarrhea and nausea, are among the most frequently reported adverse reactions for the ampicillin component. These common effects result from the antibiotic disrupting the balance of gut flora. If these symptoms are severe or persistent, regulatory documents advise seeking a medical evaluation.


Q: Is feeling tired or fatigued a common side effect of Meticil?

A: Feeling tired or having general malaise (a feeling of discomfort or illness) has been reported in postmarketing experience with the ampicillin component. While these systemic effects are not listed among the most frequent reactions, they are documented in regulatory reports as possible side effects.


Q: What happens if I accidentally miss a dose of Meticil?

A: Official patient guidance states that if a dose is missed, it should generally be taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, official guidance indicates the missed dose is typically skipped. It is advised never to take two doses simultaneously.


Q: What happens if I accidentally take an extra dose of Meticil?

A: Regulatory documents describe that in cases of potential overdose, individuals should seek emergency medical attention or contact a Poison Help line. This is particularly important if the taken dose exceeds the standard prescribed limits.


Q: Is Meticil safe to take during pregnancy?

A: Regulatory documents indicate that the Ampicillin component has been classified in Pregnancy Category B. The Diclofenac component, however, is contraindicated (should not be used) from 30 weeks gestation and later due to potential fetal risk. The determination of use is based on the prescribing professional's evaluation of the specific risks and benefits at different stages.


Q: Is Meticil safe to use while breastfeeding?

A: Official sources note that low levels of the ampicillin component can pass into breast milk. While adverse effects in the infant are generally not expected, caution is advised because antibacterials can potentially disrupt the infant's gastrointestinal flora, leading to effects such as diarrhea or thrush.


Q: Is it true that Meticil can affect the 'good' bacteria in my body?

A: Yes, regulatory warnings note that treatment with antibacterial agents like Meticil alters the normal bacterial flora (the 'good' bacteria) in the colon. This alteration is known to occur as a consequence of broad-spectrum antibiotic use, and can occasionally lead to the overgrowth of harmful bacteria, such as Clostridium difficile.


Q: What kind of studies have been done on Meticil?

A: The research base for Meticil's components includes Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitor the antibiotic component's relationship to microbiological clearance (the killing of bacteria) and the symptom management effects of the anti-inflammatory component on pain and fever.


Q: What types of infections is Meticil typically used to treat?

A: The ampicillin component is indicated for treating infections caused by susceptible organisms. These typically include infections of the Urinary Tract (UTIs), certain respiratory tract infections, gastrointestinal infections, and skin and soft tissue infections.


Q: Can Meticil also help with infections caused by viruses, like the common cold or flu?

A: Official regulatory labels are explicit that antibacterials, including the ampicillin component in Meticil, will not treat viral infections such as the common cold or the flu. Antibiotics are only effective against bacterial infections.


Q: How quickly should I expect to see an improvement after starting Meticil?

A: Regulatory information advises that patients' symptoms may begin to improve before the infection is completely cleared. Regulatory information emphasizes that improvement does not mean the full course should be discontinued.


Q: Why do doctors prescribe Meticil instead of other antibiotics?

A: Meticil is a fixed-dose combination product containing both an antibiotic (Ampicillin) and an NSAID (Diclofenac). The rationale, according to official documents, is to address both the underlying bacterial infection and the associated inflammatory symptoms like pain and fever simultaneously, representing a streamlined approach.


Q: If I start feeling better, is it okay to stop taking Meticil sooner than the full course?

A: Regulatory patient information describes the importance of using the medicine for the full prescribed length of time. Stopping before the full duration is completed is associated with an increased risk of the original infection recurring or the development of drug-resistant bacteria.


Q: Can a person become resistant to Meticil, or is it the bacteria?

A: The phenomenon is called antimicrobial resistance (AMR), which is the ability of microorganisms (the bacteria themselves) to resist the effects of the antibacterial drug. The person does not become resistant, but the drug becomes less effective against the bacteria causing the infection.


Q: Is there a risk of developing a secondary infection, like a yeast infection, when taking Meticil?

A: Official warnings advise that the possibility of superinfections with mycotic (fungal, such as a yeast infection) or other bacterial pathogens should be considered. This occurs when the antibiotic alters the body’s natural bacterial balance.


Q: Why do some people take Meticil with food and others take it on an empty stomach?

A: The oral Ampicillin component's absorption is maximized when taken on an empty stomach (one hour before or two hours after meals). However, regulatory guidance also advises taking it with food (at the start of a meal) to enhance gastrointestinal tolerance, leading to different instructions based on the priority.


Q: What should I do if my symptoms seem to be getting worse while taking Meticil?

A: Official regulatory documents describe that if symptoms do not improve or begin to get worse during treatment, contacting a medical professional is advised. This requires prompt medical re-evaluation to determine the best course of action.


Q: Can Meticil be used to treat skin infections?

A: Yes, the ampicillin component is indicated for the treatment of certain skin and soft tissue infections caused by susceptible bacteria, according to regulatory labels.


Q: Does Meticil work for urinary tract infections (UTIs)?

A: Yes, the ampicillin component is included in the regulatory indications for the treatment of Urinary Tract Infections (UTIs) caused by specific types of susceptible bacteria.


Q: Does the efficacy of Meticil decrease over time, like with other antibacterials?

A: Regulatory documents indicate that the development of antimicrobial resistance occurs over time. Misuse of the drug increases the risk of promoting drug-resistant bacteria, which could decrease the drug's future effectiveness against those resistant organisms.


Q: Is Meticil known to cause any long-term side effects after the treatment course is finished?

A: Regulatory warnings highlight that some serious reactions, such as Clostridium difficile-associated diarrhea (CDAD), have been reported to occur two months or more after antibacterial administration is stopped. Furthermore, animal studies of the drug have shown carcinogenic activity, leading to warnings against unnecessary use.


Q: How long does Meticil stay in the body after the last dose?

A: The time it takes for the concentration of the medicine to drop by half (the mean serum half-life) is approximately one hour for the ampicillin component in healthy individuals. The Diclofenac component has a half-life of approximately two hours. The drug is largely eliminated from the body within a few hours.


Q: Is there anything I should avoid eating or drinking while taking Meticil, besides alcohol?

A: Regulatory warnings strictly advise avoiding alcohol and products containing propylene glycol. While no other specific foods or drinks are formally listed as contraindications, food can affect the absorption of the ampicillin component.


Q: Can Meticil cause dizziness or affect my ability to drive?

A: Official reports for the Diclofenac component include dizziness as an occasional adverse reaction. Due to the potential for dizziness, individuals are advised that their ability to operate machinery or drive may be affected.


Q: Why do I need a prescription for Meticil, but not for some other medicines?

A: Meticil is classified as a Prescription Only (Rx) medication. This is due to the nature of its active ingredients—an antibiotic and a potent NSAID—which require professional medical supervision to ensure appropriate use and monitor potential risks.


Q: What are the official safety classifications for Meticil regarding risk in certain populations?

A: Regulatory documents indicate the Ampicillin component was previously classified in Pregnancy Category B. For Lactation, caution is advised as the drug is known to pass into milk, requiring careful consideration of the risks to the infant's gastrointestinal health.


Q: Why is Meticil sometimes given to prevent infection instead of just treating it?

A: In some official guidelines, the ampicillin component is indicated for prophylaxis (prevention) in specific situations. A common example is endocarditis prophylaxis (prevention of heart lining infection) before certain procedures in high-risk patients.


Q: Is it normal to have a slight rash while taking Meticil?

A: Skin rashes and hives (urticaria) are among the most frequently reported adverse effects of the ampicillin component. However, regulatory documents advise that any new rash should be reported promptly to a healthcare provider to distinguish a common reaction from a potentially severe skin reaction.


Q: Is Meticil available in generic form?

A: The individual components of Meticil, specifically the ampicillin component, are widely available in generic forms according to regulatory and related FDA guidance, which may be a lower-cost alternative to the original brand-name product.

How should Meticil (ANTIBACTERIALS) be stored and disposed of?

How to Store and Dispose of Meticil (ANTIBACTERIALS)?

Proper storage and disposal are essential to maintain the effectiveness and safety of Meticil (methicillin, or other antibacterials classified as Meticil) and prevent environmental contamination. Always follow the instructions provided by your pharmacist or healthcare provider.


Storage

Meticil should be stored at room temperature (between 68 F and 77 F or 20 C and 25 C) away from excess heat and moisture. Do not store it in the bathroom. Keep the medication in its original container, tightly closed, and out of the reach of children and pets.


Disposal

Do not flush unused or expired Meticil down the toilet or pour it down a drain unless specifically instructed to do so. The preferred method of disposal is to take it to a drug take-back program. If a take-back program is unavailable, mix the medication with an undesirable substance, like kitty litter or used coffee grounds, place it in a sealed bag or container, and discard it in your household trash. Remove all personal identifying information from the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meticil (ANTIBACTERIALS) found in:

A-Z Index: